Nicola Silvestris

Summary

Affiliation: National Cancer Institute
Country: Italy

Publications

  1. doi request reprint Optimized granulocyte colony-stimulating factor prophylaxis in adult cancer patients: from biological principles to clinical guidelines
    Nicola Silvestris
    Cancer Institute Giovanni Paolo II, Medical and Experimental Oncology Unit, Viale Orazio Flacco, 65, 70124 Bari, Italy
    Expert Opin Ther Targets 16:S111-7. 2012
  2. pmc Natural history of malignant bone disease in gastric cancer: final results of a multicenter bone metastasis survey
    Nicola Silvestris
    Medical Oncology Unit, National Cancer Research Centre Istituto Tumori Giovanni Paolo II, Bari, Italy
    PLoS ONE 8:e74402. 2013
  3. pmc Natural history of malignant bone disease in renal cancer: final results of an italian bone metastasis survey
    Daniele Santini
    Department of Medical Oncology, University Campus Bio Medico, Rome, Italy
    PLoS ONE 8:e83026. 2013
  4. ncbi request reprint Target therapies in pancreatic carcinoma
    Nicola Silvestris
    Medical Oncology Unit, National Cancer Research Centre Istituto Tumori Giovanni Paolo II, Viale Orazio Flacco, 65, 70124 Bari, Italy
    Curr Med Chem 21:948-65. 2014
  5. pmc Carcinogenesis of pancreatic adenocarcinoma: precursor lesions
    Antonio Gnoni
    Medical Oncology Unit, Hospital Vito Fazzi, Lecce 73100, Italy
    Int J Mol Sci 14:19731-62. 2013
  6. pmc Expression and prognostic value of VEGFR-2, PDGFR-β, and c-Met in advanced hepatocellular carcinoma
    Jie Sheng Chu
    The Affiliated Hospital Cancer Center, Academy of Military Medical Sciences, Beijing 100071, People s Republic of China
    J Exp Clin Cancer Res 32:16. 2013
  7. ncbi request reprint Unique case of giant adult paratesticular spindle cell rhabdomyosarcoma
    Nicola Silvestris
    Medical and Experimental Oncology Unit, Scientific Institute for Research and Treatment of Cancer Giovanni Paolo II Bari, Bari, Italy
    Urology 73:500-2. 2009
  8. ncbi request reprint Successful treatment with three-weekly paclitaxel of an anthracycline-refractory classical Kaposi's sarcoma
    Nicola Silvestris
    Medical and Experimental Oncology Unit, Oncology Institute Giovanni Paolo II, Bari, Italy
    Anticancer Res 29:675-6. 2009
  9. ncbi request reprint KRAS mutations and sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal carcinoma: an open issue
    Nicola Silvestris
    Scientific Institute for Research and Treatment of Cancer Giovanni Paolo II, Medical and Experimental Oncology Unit, Bari, Italy
    Expert Opin Biol Ther 9:565-77. 2009
  10. doi request reprint The dark side of the moon: the PI3K/PTEN/AKT pathway in colorectal carcinoma
    Nicola Silvestris
    Medical and Experimental Oncology Unit, Cancer Institute Giovanni Paolo II, Bari, Italy
    Oncology 77:69-74. 2009

Detail Information

Publications39

  1. doi request reprint Optimized granulocyte colony-stimulating factor prophylaxis in adult cancer patients: from biological principles to clinical guidelines
    Nicola Silvestris
    Cancer Institute Giovanni Paolo II, Medical and Experimental Oncology Unit, Viale Orazio Flacco, 65, 70124 Bari, Italy
    Expert Opin Ther Targets 16:S111-7. 2012
    ....
  2. pmc Natural history of malignant bone disease in gastric cancer: final results of a multicenter bone metastasis survey
    Nicola Silvestris
    Medical Oncology Unit, National Cancer Research Centre Istituto Tumori Giovanni Paolo II, Bari, Italy
    PLoS ONE 8:e74402. 2013
    ..Bone metastasis represents an increasing clinical problem in advanced gastric cancer (GC) as disease-related survival improves. In literature, few data on the natural history of bone disease in GC are available...
  3. pmc Natural history of malignant bone disease in renal cancer: final results of an italian bone metastasis survey
    Daniele Santini
    Department of Medical Oncology, University Campus Bio Medico, Rome, Italy
    PLoS ONE 8:e83026. 2013
    ..Bone metastasis represents an increasing clinical problem in advanced renal cell carcinoma (RCC) as disease-related survival improves. There are few data on the natural history of bone disease in RCC...
  4. ncbi request reprint Target therapies in pancreatic carcinoma
    Nicola Silvestris
    Medical Oncology Unit, National Cancer Research Centre Istituto Tumori Giovanni Paolo II, Viale Orazio Flacco, 65, 70124 Bari, Italy
    Curr Med Chem 21:948-65. 2014
    ..The knowledge of biologic and molecular aspects of pancreatic cancer can be the basis for future therapeutic developments. ..
  5. pmc Carcinogenesis of pancreatic adenocarcinoma: precursor lesions
    Antonio Gnoni
    Medical Oncology Unit, Hospital Vito Fazzi, Lecce 73100, Italy
    Int J Mol Sci 14:19731-62. 2013
    ..In this scenario, highlighting these molecular alterations could provide new clinical tools for early diagnosis and new effective therapies for this malignancy. ..
  6. pmc Expression and prognostic value of VEGFR-2, PDGFR-β, and c-Met in advanced hepatocellular carcinoma
    Jie Sheng Chu
    The Affiliated Hospital Cancer Center, Academy of Military Medical Sciences, Beijing 100071, People s Republic of China
    J Exp Clin Cancer Res 32:16. 2013
    ..We explore the clinical and prognostic significance of expression of vascular endothelial growth factor receptor (VEGFR)-2, platelet-derived growth factor receptor (PDGFR)-β, and c-Met in patients with hepatocellular carcinoma (HCC)...
  7. ncbi request reprint Unique case of giant adult paratesticular spindle cell rhabdomyosarcoma
    Nicola Silvestris
    Medical and Experimental Oncology Unit, Scientific Institute for Research and Treatment of Cancer Giovanni Paolo II Bari, Bari, Italy
    Urology 73:500-2. 2009
    ..The final pathological diagnosis was paratesticular spindle cell rhabdomyosarcoma. Unfortunately, few days after surgery, patient presented a clinical and laboratory picture of disseminated intravascular coagulation followed by exitus...
  8. ncbi request reprint Successful treatment with three-weekly paclitaxel of an anthracycline-refractory classical Kaposi's sarcoma
    Nicola Silvestris
    Medical and Experimental Oncology Unit, Oncology Institute Giovanni Paolo II, Bari, Italy
    Anticancer Res 29:675-6. 2009
    ....
  9. ncbi request reprint KRAS mutations and sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal carcinoma: an open issue
    Nicola Silvestris
    Scientific Institute for Research and Treatment of Cancer Giovanni Paolo II, Medical and Experimental Oncology Unit, Bari, Italy
    Expert Opin Biol Ther 9:565-77. 2009
    ..However, this method is not predictive of treatment efficacy. KRAS, the human homolog of the Kirsten rat sarcoma-2 virus oncogene, encodes a small G-protein that functions downstream of EGFR-induced signalling...
  10. doi request reprint The dark side of the moon: the PI3K/PTEN/AKT pathway in colorectal carcinoma
    Nicola Silvestris
    Medical and Experimental Oncology Unit, Cancer Institute Giovanni Paolo II, Bari, Italy
    Oncology 77:69-74. 2009
    ..The introduction of modulators of the PI3K/AKT/mTOR pathway as potential targeted anticancer drugs is encouraging, but this attractive therapy option is still at an early stage of development...
  11. doi request reprint Update on capecitabine alone and in combination regimens in colorectal cancer patients
    N Silvestris
    Medical Oncology Department, National Cancer Institute Giovanni Paolo II, Via Hahnemann 10, Bari, Italy
    Cancer Treat Rev 36:S46-55. 2010
    ....
  12. ncbi request reprint Pharmacokinetic and metabolism determinants of fluoropyrimidines and oxaliplatin activity in treatment of colorectal patients
    Antonio Gnoni
    Clinical Experimental Oncology Laboratory, National Cancer Institute Giovanni Paolo II, Viale Orazio Flacco, 65 70124 Bari, Italy
    Curr Drug Metab 12:918-31. 2011
    ....
  13. ncbi request reprint Intravenous versus oral vinorelbine plus capecitabine as second-line treatment in advanced breast cancer patients. A retrospective comparison of two consecutive phase II studies
    Vito Lorusso
    Medical Oncology Unit, Vito Fazzi Hospital, Lecce, Italy
    Breast 19:214-8. 2010
    ....
  14. ncbi request reprint Targeting EGFR in bilio-pancreatic and liver carcinoma
    Maria Elisabetta Fratto
    Medical Oncology, University Campus Bio Medico, Rome
    Front Biosci (Schol Ed) 3:16-22. 2011
    ..Patient selection by use of biologic markers will identify which patients are more likely to respond, contributing to the successful use of these agents...
  15. doi request reprint Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study
    Giuseppe Colucci
    Medical and Experimental Oncology Unit, Cancer Institute Giovanni Paolo II, Bari, Italy
    Oncology 79:415-22. 2010
    ..The purpose of this phase II study was to evaluate the activity and safety of FOLFOX-4 plus cetuximab in untreated mCRC patients...
  16. doi request reprint Oncosuppressor methylation: a possible key role in colon metastatic progression
    Stefania Tommasi
    Clinical Experimental Oncology Laboratory, National Cancer Centre Giovanni Paolo II, Bari, Italy
    J Cell Physiol 226:1934-9. 2011
    ..These evidences held the role of oncosuppressor methylation in both colon tumorigenesis and progression and suggested that epigenetic events should be taken into account when biological therapies in mCRC patients have to be set...
  17. ncbi request reprint Topotecan in the treatment of brain metastases. A phase II study of GOIM (Gruppo Oncologico dell'Italia Meridionale)
    Vito Lorusso
    Medical Oncology Department, Oncology Institute, Via Amendola 209, 70123 Bari, Italy
    Anticancer Res 26:2259-63. 2006
    ..Topotecan is able to cross the blood-brain barrier (BBB) and has been demonstrated to be active in brain metastases from small cell lung cancer (SCLC)...
  18. ncbi request reprint Nti-EGFR monoclonal antibody in cancer treatment: in vitro and in vivo evidence
    Anna Elisa Quatrale
    Clinical Experimental Oncology Laboratory, National Cancer Institute Giovanni Paolo II, Via Hahnemann 10, 70126 Bari, Italy
    Front Biosci (Landmark Ed) 16:1973-85. 2011
    ....
  19. doi request reprint Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV
    Bruno Vincenzi
    Medical Oncology, Università Campus Bio Medico, Via Alvaro del Portillo 200, 00128, Rome, Italy
    Support Care Cancer 21:1313-9. 2013
    ..Oxaliplatin-induced neuropathy is a dose-related side effect which occurs in almost 40 % of patients treated with oxaliplatin. Aim of the present study was to identify reliable clinical factors predicting its development and duration...
  20. ncbi request reprint Topotecan plus ifosfamide in patients with platinum refractory advanced/metastatic non-small cell lung cancer: a phase II trial
    Vito Lorusso
    Department of Medical Oncology, Oncology Institute, Via Amendola 209, 70126 Bari, Italy
    Oncol Rep 14:1547-51. 2005
    ..7%. Nevertheless, the still low response rate and the shortness of median survival indicates the need for more effective second line treatments in this disease...
  21. pmc High density of tryptase-positive mast cells in human colorectal cancer: a poor prognostic factor related to protease-activated receptor 2 expression
    Andrea Malfettone
    Functional Biomorphology Laboratory, National Cancer Research Centre, Giovanni Paolo II, Bari, Italy
    J Cell Mol Med 17:1025-37. 2013
    ..Our data indicate that the high density of tryptase(+) MCs at invasive margins of tumours was associated with advanced stages of CRC and was strongly correlated with PAR-2 expression. ..
  22. ncbi request reprint A phase I study of capecitabine in combination with vinorelbine in advanced breast cancer
    Vito Lorusso
    Medical Oncology Department, Oncology Institute of Bari, Italy
    Clin Breast Cancer 4:138-41. 2003
    ....
  23. ncbi request reprint Sunitinib in malignant melanoma: a treatment option only for KIT-mutated patients?
    Daniele Santini
    Medical Oncology, University Campus Bio Medico, Rome, Italy
    Future Oncol 9:1809-11. 2013
    ..To our knowledge, this represents the first evidence of sunitinib activity in KIT wild-type melanoma. Further studies should be performed to confirm these preliminary data...
  24. doi request reprint Is the combination of Cetuximab with chemo-radiotherapy regimens worthwhile in the treatment of locally advanced head and neck cancer? A review of current evidence
    Gianmauro Numico
    Medical Oncology Department, Ospedale U Parini, Aosta, Italy
    Crit Rev Oncol Hematol 85:112-20. 2013
    ..Single local and systemic toxicities are more frequent and supposedly the overall treatment intensity is increased. Moreover the drug-specific toxicities are potentially severe and deserve timely recognition and management...
  25. ncbi request reprint Predictive factors to targeted treatment in gastrointestinal carcinomas
    Nicola Silvestris
    Medical Oncology Unit, National Cancer Research Centre Giovanni Paolo II, Bari, Italy
    Cancer Biomark 14:151-62. 2014
    ....
  26. doi request reprint Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity
    Letizia Porcelli
    Clinical and Preclinical Pharmacology Laboratory, National Cancer Research Center Giovanni Paolo II, Viale O Flacco, 65, 70124 Bari, Italy
    Mol Oncol 7:308-22. 2013
    ..For the first time, the rationale of using a PARP inhibitor as chemoradiosensitizer in pancreatic cancer models has been hypothesized and demonstrated...
  27. ncbi request reprint The coordinated role of CYP450 enzymes and P-gp in determining cancer resistance to chemotherapy
    Amalia Azzariti
    Clinical Experimental Oncology Laboratory, National Cancer Institute Giovanni Paolo II, Viale Orazio Flacco, 65 70124 Bari, Italy
    Curr Drug Metab 12:713-21. 2011
    ....
  28. doi request reprint Complete response to second line Paclitaxel every 2 weeks of eyelid kaposi sarcoma: a case report
    Anna Elisabetta Brunetti
    Scientific Direction, Hematology Unit, Medical and Experimental Oncology Unit, Cancer Institute Giovanni Paolo II, Bari, Italy
    Ophthal Plast Reconstr Surg 29:e114-5. 2013
    ..In conclusion, eyelid Kaposi sarcoma was successfully treated with paclitaxel every 2 weeks, obtaining a complete response...
  29. ncbi request reprint Dasatinib: an anti-tumour agent via Src inhibition
    Antonio Gnoni
    Medical Oncology Unit, Hospital Vito Fazzi, Lecce, Italy
    Curr Drug Targets 12:563-78. 2011
    ....
  30. doi request reprint Co-expression of CD133(+)/CD44(+) in human colon cancer and liver metastasis
    Antonia Bellizzi
    Invasion and Metastatization Laboratory, Department of Experimental Oncology, National Cancer Centre Giovanni Paolo II, Bari, Italy
    J Cell Physiol 228:408-15. 2013
    ..Our data demonstrate that metastatic properties of cell populations from blood and liver metastasis, differently from primitive tumors, seem to be strictly related to the phenotype CD133 positive and CD44 positive...
  31. ncbi request reprint EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence
    Anna Elisa Quatrale
    Clinical Experimental Oncology Laboratory, National Cancer Institute Giovanni Paolo II, Via Hahnemann 10, 70126 Bari, Italy
    Front Biosci (Landmark Ed) 16:1962-72. 2011
    ....
  32. ncbi request reprint EGFR status and prognosis of patients with locally advanced head and neck cancer treated with chemoradiotherapy
    Gianmauro Numico
    Department of Medical Oncology, Ospedale Regionale della Valle D Aosta, Viale Ginevra 3, 11100, Aosta, Italy
    Anticancer Res 30:671-6. 2010
    ..We assessed the relationship between EGFR status and outcome in patients treated with concurrent chemoradiotherapy...
  33. ncbi request reprint Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine
    Gianmauro Numico
    Department of Medical Oncology, S Croce General Hospital, Cuneo, Italy
    Cancer 103:994-9. 2005
    ..However, vascular events (VEs) seldom are considered adverse effects of treatment and may not even be taken into account in reports of chemotherapy trials...
  34. doi request reprint Overexpression of nuclear NHERF1 in advanced colorectal cancer: association with hypoxic microenvironment and tumor invasive phenotype
    Andrea Malfettone
    Functional Biomorphology Laboratory, National Cancer Centre Giovanni Paolo II, Bari, Italy
    Exp Mol Pathol 92:296-303. 2012
    ..Our results support the oncogenic role of NHERF1 and promote nuclear NHERF1 as a potential new biomarker of advanced CRC...
  35. ncbi request reprint Third-line trabectedin for a metastatic desmoplastic small round cell tumour treated with multimodal therapy
    Anna Elisabetta Brunetti
    Medical Oncology Unit, National Cancer Institute Giovanni Paolo II, Bari, Italy
    Anticancer Res 34:3683-8. 2014
    ..Conclusion: Trabectedin may be a treatment option in multimodal therapy for the management of DSRCT and warrants further research to explore the impact of trabectedin in the treatment of this disease. ..
  36. ncbi request reprint Docetaxel in advanced gastric cancer--review of the main clinical trials
    Serena Di Cosimo
    Division of Medical Oncology A, Regina Elena Cancer Institute, Rome, Italy
    Acta Oncol 42:693-700. 2003
    ..The future results of the above phase III studies could indicate docetaxel as a key drug to improve treatment of patients with advanced gastric cancer...
  37. ncbi request reprint p53 as the main traffic controller of the cell signaling network
    Sinto Sebastian
    Clinical Experimental Oncology Laboratory, National Cancer Institute Giovanni Paolo II, Via Hahnemann, 10 70126 Bari, Italy
    Front Biosci (Landmark Ed) 15:1172-90. 2010
    ..This review highlights how p53 signaling activity is altered in cancer cells so that cells acquire the hallmarks of cancer including deregulated infinite self replicative potential...
  38. pmc Clinical and organizational issues in the management of surviving breast and colorectal cancer patients: attitudes and feelings of medical oncologists
    Gianmauro Numico
    Medical Oncology Unit, Azienda USL della Valle d Aosta, Aosta, Italy
    PLoS ONE 9:e101170. 2014
    ..A survey aimed at assessing attitudes and feelings of oncologists was considered preliminary to further initiatives...
  39. ncbi request reprint AIDS-related non-Hodgkin's lymphoma: clinico-pathological characteristics and therapeutic strategies (review)
    Nicola Silvestris
    Operative Unit of Medical Oncology, ASL of Frosinone, Bari, Italy
    Int J Oncol 20:611-5. 2002
    ..We reviewed the main clinico-pathological features of this disease and analysed its pathogenetic mechanisms with potential therapeutic implications...